Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
Poseltinib
Другие языки:

    Poseltinib

    Подписчиков: 0, рейтинг: 0
    Poseltinib
    Poseltinib.svg
    Clinical data
    Other names HM-7122; LY 3337641
    Identifiers
    • N-(3-((2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide
    CAS Number
    PubChem CID
    UNII
    Chemical and physical data
    Formula C26H26N6O3
    Molar mass 470.533 g·mol−1
    3D model (JSmol)
    • C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1
    • InChI=1S/C26H26N6O3/c1-3-23(33)27-19-5-4-6-21(17-19)35-25-24-22(11-16-34-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)
    • Key:LZMJNVRJMFMYQS-UHFFFAOYSA-N

    Poseltinib (HM71224, LY3337641) is an experimental Bruton's tyrosine kinase inhibitor for the treatment of rheumatoid arthritis. It was developed by Hanmi Pharmaceutical and licensed to Eli Lilly.

    Phase II clinical trials began in August 2016 in patients with rheumatoid arthritis. Additional phase II trials are planned for treatment of lupus, lupus nephritis, Sjögren's syndrome, and other immunological conditions.


    Новое сообщение